Aigen Investment Management LP Raises Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Aigen Investment Management LP raised its holdings in Illumina, Inc. (NASDAQ:ILMNFree Report) by 214.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,187 shares of the life sciences company’s stock after buying an additional 3,538 shares during the quarter. Aigen Investment Management LP’s holdings in Illumina were worth $722,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. abrdn plc raised its stake in Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after buying an additional 299,827 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Illumina in the third quarter valued at about $29,558,000. International Assets Investment Management LLC raised its stake in Illumina by 210.5% in the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock valued at $6,711,000 after buying an additional 32,672 shares during the last quarter. Victory Capital Management Inc. raised its stake in Illumina by 5.9% in the fourth quarter. Victory Capital Management Inc. now owns 122,743 shares of the life sciences company’s stock valued at $17,091,000 after buying an additional 6,827 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Illumina by 49.0% in the fourth quarter. BNP Paribas Financial Markets now owns 275,762 shares of the life sciences company’s stock valued at $38,397,000 after buying an additional 90,634 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Jacob Thaysen bought 7,330 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ILMN. Scotiabank cut their price objective on Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a report on Monday, May 6th. Barclays increased their price objective on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. OTR Global reissued a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average price target of $164.65.

Read Our Latest Stock Report on Illumina

Illumina Price Performance

ILMN traded up $1.20 during trading on Wednesday, hitting $108.81. The company’s stock had a trading volume of 525,311 shares, compared to its average volume of 1,706,293. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $213.91. The business’s fifty day simple moving average is $124.04 and its 200 day simple moving average is $126.91. The firm has a market capitalization of $17.33 billion, a price-to-earnings ratio of -13.20 and a beta of 1.20.

Illumina (NASDAQ:ILMNGet Free Report) last released its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 earnings per share. On average, equities research analysts forecast that Illumina, Inc. will post 0.87 EPS for the current fiscal year.

Illumina Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

See Also

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.